期刊文献+

缬沙坦联合贝那普利治疗肾性高血压的临床疗效 被引量:6

Clinical curative effect of valsartan combined with benazepril on renal hypertension
在线阅读 下载PDF
导出
摘要 目的观察缬沙坦与贝那普利联合用药和氨氯地平与贝那普利联合治疗肾性高血压的临床疗效比较。方法 60例患者随机分为两组:观察组(30例)予缬沙坦每次80 mg,每日一次,贝那普利每次10 mg,每日一次;对照组(30例)予贝那普利每次10 mg,每日一次,氨氯地平每次5 mg,每日一次;疗程共2个月,观察治疗结果并进行比较。结果两组治疗后血压均明显下降(P<0.01),观察组下降幅度大于对照组,差异有统计学意义(P<0.05)。两组治疗后24 h尿蛋白定量明显减少,Scr显著降低,差异有统计学意义(P<0.05)。观察组24 h尿蛋白改善比对照组明显,差异有统计学意义(P<0.05);而在血肌酐方面,观察组变化幅度大于对照组,差异无统计学意义(P>0.05)。结论 ACEI+ARB联合用药,除有效控制肾性高血压外,在肾脏保护方面强于应用ACEI+CCB。 Objective To compare the difference in the clinical curative effect of benazepril combined with valsartan or amlodipine in the treatment of renal hypertension. Methods The 60 patients with renal hypertension were randomly divided into the observation group (30 cases) and the control group (30 cases). The former was given valsartan 80mg and benazepril 10mg once a day. The latter was given amlodipine 5rag and benazepril 10 mg once a day. The clinical curative effect of the two groups was observed and compared after 2 months. Results The blood pressure in the two groups after treatment all decreased significantly (P〈0.01). the observation group dropped greater than the control group, the difference was statistically significant (P〈0.05). The quantity of 24-hour urine protein excretion and serum creatinine in the two groups decreased significantly after treatment., the difference was also statistically significant (P〈0.05). The improvement of 24-hour urine protein in the observation group was better than in the control group obviously, the difference was statistically significant (/9〈0.05). In respect of serum ereatinine, the observation group varied than the control group, but the difference no statistical significance (P〉0.05). Conclusion ACEI combined with ARB can effectively control the renal hypertension. In addition, they are stronger than ACEI and CCB in the protection of renal function.
出处 《中国现代医生》 2013年第32期89-90,共2页 China Modern Doctor
关键词 缬沙坦 贝那普利 肾性高血压 Valsartan Benazepril Renal hypertension
  • 相关文献

参考文献6

二级参考文献25

  • 1王玉,李晓玫.慢性肾脏病与高血压相关研究的热点问题[J].中国实用内科杂志,2007,27(10):814-818. 被引量:16
  • 2侯凡凡,谢迪.慢性肾脏病的治疗——合理降压控制尿蛋白逆转肾小球硬化[J].中国实用内科杂志,2007,27(13):1010-1012. 被引量:29
  • 3Weinberg AJ,Zappe DH,Ramadugu R,et al.Long-term safety of high-dose angiotensin receptor blocker therapy in hypertensive patients with chronic kidney disease[J].Hypertens SUPPL,2006,24(1):95-99
  • 4Foga AB.Progression versus regression of chronic kidney disease[J].Nephrol Dial Transplant,2006,21(2):280-284
  • 5Nakao N,Yoshimura A,Morita H,et al.Combination treatment of angiotensin-II receptor blocker and angiotensin-converting enzyme inhibitor in non-diabetic renal disease(COOPERATE):a randomized controlled trial[J].Lancet,2003,361 (9352):117-124
  • 6Lea J, Greene T, Hebert L, et al. The relationship between magnitude of prote - inuria reduction and risk of end - stage renal disease : results of the African American study of kidney disease and hypertension [J]. Arch Intern Med, 2005, 165:947 -953.
  • 7Tumas Berl. Renal protection by inhibition of the renin - angiotensinal-dusterone system [ J]. Renin Angiotensin Aldosterone Syst 2009, 10 : 1-8.
  • 8Remuzzi G, Benigni A, Remuzzi A. Mechanisms of progression and regression of renal lesions of chronic nephropathies and diabetes [ J ]. Clin Invest, 2006, 116: 288-296.
  • 9De Zeeuw D, Remuzzi G, Parring HH, et al. Proteinuria, a target for renoproteetion in patients with type 2 diabetic nephropathy: lessons from RENAAL [J]. Kidney Int, 2004, 65: 2309-2320.
  • 10Atkins RC, Briganti EM, Lewis JB, et al. Proteinuria reduction and progression to renal failure in patients with type 2 diabetes mellitus and overt nephropathy [J]. Am J Kidney Dis, 2005, 45:281-287.

共引文献23

同被引文献60

  • 1李洪林,何文生.联合应用氯沙坦或贝那普利强化降压治疗高血压并2型糖尿病肾病的疗效观察[J].中国医药指南,2008,6(20):55-57. 被引量:3
  • 2韩荣旗,雷亚峰,杨应军,武俊.肾性高血压降压药物的合理选用[J].世界临床药物,2013,34(4):245-248. 被引量:10
  • 3刘志康,许亚宏,李健,马小平,汤锋,李宏辉.厄贝沙坦和贝那普利联合治疗肾性高血压的临床观察[J].西南国防医药,2004,14(4):379-381. 被引量:1
  • 4陈楠,陈佳韵.重视微量白蛋白尿的筛查与诊治[J].实用医院临床杂志,2005,2(1):17-19. 被引量:26
  • 5苏定冯.心血管药理学[M].4版.北京:人民卫生出版社,2011:501-537.
  • 6杨宝峰.药理学[M].8版.北京:人民卫生出版社,2013:1-484.
  • 7Soucek M, Monhart V, Nedb61kov6 M. Hy- pertension and cardiovascular complications of chronic renal failure [J]. Vnitr Lek, 2011,57 (7/8): 615-619.
  • 8Adarkwah CC, Gandjour A, Akkerman M, et al. Cost - effectiveness of angiotensin - converting enzyme inhibitors for the prevention of diabetic nephropathy in The Netherlands - a Markov model [J].PLoS One, 2011, 6 (10) : e26139.
  • 9Bakris GL, Sarafidis PA, Weir MR, et al. Renal outcomes with different fixed - dose combination therapies in patients with hyper- tension at high risk for cardiovascular events (ACCOMPLISH) : a prespecified secondary analysis of a randomised controlled trial [ J ]. Lancet, 2010, 375 (9721): 1173-1151.
  • 10Baltatzi M, Savopoulos Ch, Hatzitolios A. Role of angiotensin converting enzyme inhibi-tors and angiotensin receptor blockers in hy- pertension of chronic kidney disease and renoprotection. Study results [J]. Hipp- okratia, 2011, 15 (Supp| 1): 27-32.

二级引证文献58

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部